UNSPSC 51111862: Nilotinib

This classification denotes a tyrosine kinase inhibitor with the molecular formula C28H22F3N7O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F41401512X. European Medicines Agency schedules nilotinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25225. The term NILOTINIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56). Most nations schedule nilotinib under HS 29335990 and SITC 51576.

As of Q4 2014, NILOTINIB remains the US FDA Preferred Term for this commodity. Nilotinib bears US NLM identifiers UMLS ID C1721377 and NCI Concept Code C48375. SMILES: CL.FC(F)(F)C1CC(N2CC(NC2)C)CC(NC(=O)C2CC(NC3NC(C4CCCNC4)CCN3)C(CC2)C)C1.O.

UNSPSC 51111862 Nilotinib, a Commodity code, describes a specific pharmaceutical product — the tyrosine kinase inhibitor used primarily in chronic myeloid leukemia treatment — that state and local health systems and cooperative purchasing alliances procure as part of broader multi-source generic pharmaceutical contracts. Recent state and local solicitations under this code show that issuing bodies buy nilotinib alongside hundreds of other generic drugs and OTC products through cooperative purchasing vehicles that consolidate demand across multiple jurisdictions and authorized pharmaceutical wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body soliciting under this code; MMCAP coordinates procurement on behalf of participating state agencies, counties, municipalities, and other local government facilities across multiple states including Oregon. Vendors respond to these solicitations by providing comprehensive pricing and product data for specific National Drug Codes, certifying compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintaining contractual relationships with authorized wholesalers including AmerisourceBergen (Cencara), Cardinal Health, and Morris & Dickson Co., and demonstrating pricing flexibility through flat-price, net-price, or WAC-minus structures.

MMCAP's most recent RFP, solicitation S1070000015802 posted January 20, 2026 with a March 26, 2026 response deadline, represents the primary recent activity under this code. The procurement establishes multiple contracts for generic multi-source pharmaceuticals and OTC products, with awarded vendors effective July 1, 2026 and a base contract term of two years for new responders; incumbent responders' amendments extend through June 30, 2028. Evaluation weighting heavily favors price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing credibility, administrative compliance, EDI capability, and willingness to accept MMCAP's 3 percent administrative fee. The solicitation requires vendors to carry $5 million commercial general liability insurance, $2 million network security and privacy liability coverage, and $2 million professional liability coverage, with performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. No specific set-aside designations or budget ranges are disclosed in the available documentation.